Infusystem Hld Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Infusystem Hld has an operating margin of 5.1%, meaning the company retains $5 of operating profit per $100 of revenue. This below-average margin results in a low score of 26/100, suggesting thin profitability after operating expenses. This is up from 3.3% the prior year.
Infusystem Hld's revenue grew 7.2% year-over-year to $134.9M, a solid pace of expansion. This earns a growth score of 49/100.
Infusystem Hld carries a low D/E ratio of 0.41, meaning only $0.41 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
Infusystem Hld's current ratio of 1.82 indicates adequate short-term liquidity, earning a score of 53/100. The company can meet its near-term obligations, though with limited headroom.
Infusystem Hld converts 14.4% of revenue into free cash flow ($19.4M). This strong cash generation earns a score of 72/100.
Infusystem Hld generates a 4.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 16/100. This is up from 1.7% the prior year.
Infusystem Hld scores 2.91, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($153.3M) relative to total liabilities ($46.1M). This signals moderate financial risk that warrants monitoring.
Infusystem Hld passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Infusystem Hld generates $8.72 in operating cash flow ($20.5M OCF vs $2.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Infusystem Hld earns $3.9 in operating income for every $1 of interest expense ($6.9M vs $1.8M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
This page shows Infusystem Hld (INFU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Infusystem Hld generated $134.9M in revenue in fiscal year 2024. This represents an increase of 7.2% from the prior year.
Infusystem Hld's EBITDA was $19.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.8% from the prior year.
Infusystem Hld generated $19.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 89.9% from the prior year.
Infusystem Hld reported $2.3M in net income in fiscal year 2024. This represents an increase of 168.9% from the prior year.
Infusystem Hld earned $0.11 per diluted share (EPS) in fiscal year 2024. This represents an increase of 175.0% from the prior year.
Infusystem Hld held $527K in cash against $23.9M in long-term debt as of fiscal year 2024.
Infusystem Hld had 21M shares outstanding in fiscal year 2024. This represents an increase of 0.4% from the prior year.
Infusystem Hld's gross margin was 52.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.0 percentage points from the prior year.
Infusystem Hld's operating margin was 5.1% in fiscal year 2024, reflecting core business profitability. This is up 1.9 percentage points from the prior year.
Infusystem Hld's net profit margin was 1.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 1.0 percentage points from the prior year.
Infusystem Hld's ROE was 4.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 2.4 percentage points from the prior year.
Infusystem Hld spent $1.2M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 671.2% from the prior year.
Infusystem Hld invested $1.1M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 6.6% from the prior year.
INFU Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.5M+1.3% | $36.0M+3.7% | $34.7M+2.6% | $33.8M+0.4% | $33.7M+5.3% | $32.0M+0.7% | $31.8M-0.4% | $31.9M |
| Cost of Revenue | $15.7M-2.9% | $16.1M+3.7% | $15.5M-0.5% | $15.6M-8.2% | $17.0M+9.7% | $15.5M+3.1% | $15.1M-7.6% | $16.3M |
| Gross Profit | $20.8M+4.8% | $19.9M+3.7% | $19.2M+5.2% | $18.2M+9.3% | $16.7M+1.2% | $16.5M-1.4% | $16.7M+7.0% | $15.6M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $14.4M+9.8% | $13.1M-14.2% | $15.3M+15.9% | $13.2M+14.7% | $11.5M-15.9% | $13.7M+19.1% | $11.5M+5.1% | $10.9M |
| Operating Income | $3.8M+0.9% | $3.8M+511.2% | $618K-76.4% | $2.6M+41.0% | $1.9M+319.5% | -$845K-167.6% | $1.3M-26.3% | $1.7M |
| Interest Expense | $330K-11.5% | $373K+11.0% | $336K-6.9% | $361K-25.4% | $484K+6.1% | $456K-9.3% | $503K-10.7% | $563K |
| Income Tax | $1.2M+37.9% | $847K+62.9% | $520K-60.9% | $1.3M+125.2% | $591K+417.7% | -$186K-128.4% | $655K+52.0% | $431K |
| Net Income | $2.3M-13.1% | $2.6M+1073.4% | -$267K-128.6% | $933K+30.1% | $717K+164.5% | -$1.1M-1644.4% | $72K-89.6% | $689K |
| EPS (Diluted) | $0.11-8.3% | $0.12+1300.0% | $-0.01-120.0% | $0.05+66.7% | $0.03+160.0% | $-0.05-600.0% | $0.01-66.7% | $0.03 |
INFU Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $98.9M-2.0% | $100.8M-3.3% | $104.3M+0.6% | $103.6M-4.5% | $108.5M+3.5% | $104.8M+1.9% | $102.9M+0.8% | $102.1M |
| Current Assets | $35.6M+2.2% | $34.8M-1.5% | $35.3M+9.8% | $32.2M-2.3% | $32.9M+1.4% | $32.5M+6.0% | $30.6M+3.0% | $29.7M |
| Cash & Equivalents | $955K+32.6% | $720K-52.2% | $1.5M+185.8% | $527K+261.0% | $146K-82.2% | $822K+255.8% | $231K+43.5% | $161K |
| Inventory | $5.6M-1.4% | $5.7M-7.0% | $6.1M-6.6% | $6.5M-4.5% | $6.8M+9.4% | $6.2M-2.4% | $6.4M+5.1% | $6.1M |
| Accounts Receivable | $24.3M-0.7% | $24.5M+2.5% | $23.9M+12.9% | $21.2M-0.8% | $21.3M+3.8% | $20.5M+3.6% | $19.8M+1.9% | $19.5M |
| Goodwill | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M |
| Total Liabilities | $43.4M-6.3% | $46.3M-5.7% | $49.1M+6.6% | $46.1M-16.3% | $55.0M+4.7% | $52.6M+3.9% | $50.6M0.0% | $50.6M |
| Current Liabilities | $18.7M+18.0% | $15.9M-0.7% | $16.0M-9.6% | $17.7M+11.2% | $15.9M-8.3% | $17.3M+10.2% | $15.7M+10.1% | $14.3M |
| Long-Term Debt | $20.9M-20.6% | $26.3M-8.2% | $28.7M+20.3% | $23.9M-30.2% | $34.2M+14.1% | $29.9M+2.9% | $29.1M-10.9% | $32.7M |
| Total Equity | $55.5M+1.7% | $54.5M-1.1% | $55.1M-4.1% | $57.5M+7.6% | $53.5M+2.3% | $52.3M0.0% | $52.3M+1.6% | $51.5M |
| Retained Earnings | -$61.4M+0.1% | -$61.5M-1.5% | -$60.6M-5.5% | -$57.5M+3.1% | -$59.3M+0.7% | -$59.7M-1.9% | -$58.6M+0.1% | -$58.7M |
INFU Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.5M+21.2% | $7.0M+293.8% | $1.8M-77.6% | $7.9M+243.5% | $2.3M+512.5% | $377K-91.9% | $4.7M+9.2% | $4.3M |
| Capital Expenditures | $79K-63.6% | $217K+65.6% | $131K-75.3% | $530K+57.3% | $337K+85.2% | $182K-55.4% | $408K+234.4% | $122K |
| Free Cash Flow | $8.4M+23.9% | $6.8M+311.9% | $1.6M-77.7% | $7.4M+275.3% | $2.0M+911.3% | $195K-95.4% | $4.3M+2.6% | $4.1M |
| Investing Cash Flow | -$252K+85.0% | -$1.7M+36.7% | -$2.7M+18.6% | -$3.3M+51.2% | -$6.7M-1501.9% | -$418K+60.0% | -$1.0M-248.0% | -$300K |
| Financing Cash Flow | -$8.0M-31.0% | -$6.1M-428.5% | $1.9M+141.2% | -$4.5M-221.7% | $3.7M+487.2% | $632K+117.8% | -$3.5M+10.0% | -$3.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $2.2M-38.1% | $3.5M+20.9% | $2.9M+1354.8% | $199K-29.7% | $283K | $0 | $0 | $0 |
INFU Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.1%+1.9pp | 55.2%0.0pp | 55.2%+1.4pp | 53.8%+4.4pp | 49.5%-2.0pp | 51.5%-1.1pp | 52.6%+3.7pp | 48.9% |
| Operating Margin | 10.4%-0.0pp | 10.5%+8.7pp | 1.8%-5.9pp | 7.7%+2.2pp | 5.5%+8.1pp | -2.6%-6.6pp | 3.9%-1.4pp | 5.3% |
| Net Margin | 6.2%-1.0pp | 7.2%+8.0pp | -0.8%-3.5pp | 2.8%+0.6pp | 2.1%+5.6pp | -3.5%-3.7pp | 0.2%-1.9pp | 2.2% |
| Return on Equity | 4.1%-0.7pp | 4.8% | N/A | 1.6%+0.3pp | 1.3% | N/A | 0.1%-1.2pp | 1.3% |
| Return on Assets | 2.3%-0.3pp | 2.6%+2.8pp | -0.3%-1.2pp | 0.9%+0.2pp | 0.7%+1.7pp | -1.1%-1.1pp | 0.1%-0.6pp | 0.7% |
| Current Ratio | 1.90-0.3 | 2.19-0.0 | 2.21+0.4 | 1.82-0.3 | 2.07+0.2 | 1.87-0.1 | 1.95-0.1 | 2.08 |
| Debt-to-Equity | 0.38-0.1 | 0.48-0.0 | 0.52+0.1 | 0.41-0.2 | 0.64+0.1 | 0.57+0.0 | 0.56-0.1 | 0.63 |
| FCF Margin | 23.1%+4.2pp | 18.9%+14.1pp | 4.8%-17.1pp | 21.9%+16.0pp | 5.9%+5.2pp | 0.6%-12.8pp | 13.4%+0.4pp | 13.0% |
Similar Companies
Frequently Asked Questions
What is Infusystem Hld's annual revenue?
Infusystem Hld (INFU) reported $134.9M in total revenue for fiscal year 2024. This represents a 7.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Infusystem Hld's revenue growing?
Infusystem Hld (INFU) revenue grew by 7.2% year-over-year, from $125.8M to $134.9M in fiscal year 2024.
Is Infusystem Hld profitable?
Yes, Infusystem Hld (INFU) reported a net income of $2.3M in fiscal year 2024, with a net profit margin of 1.7%.
What is Infusystem Hld's earnings per share (EPS)?
Infusystem Hld (INFU) reported diluted earnings per share of $0.11 for fiscal year 2024. This represents a 175.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Infusystem Hld's EBITDA?
Infusystem Hld (INFU) had EBITDA of $19.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Infusystem Hld have?
As of fiscal year 2024, Infusystem Hld (INFU) had $527K in cash and equivalents against $23.9M in long-term debt.
What is Infusystem Hld's gross margin?
Infusystem Hld (INFU) had a gross margin of 52.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Infusystem Hld's operating margin?
Infusystem Hld (INFU) had an operating margin of 5.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Infusystem Hld's net profit margin?
Infusystem Hld (INFU) had a net profit margin of 1.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Infusystem Hld's return on equity (ROE)?
Infusystem Hld (INFU) has a return on equity of 4.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Infusystem Hld's free cash flow?
Infusystem Hld (INFU) generated $19.4M in free cash flow during fiscal year 2024. This represents a 89.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Infusystem Hld's operating cash flow?
Infusystem Hld (INFU) generated $20.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Infusystem Hld's total assets?
Infusystem Hld (INFU) had $103.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Infusystem Hld's capital expenditures?
Infusystem Hld (INFU) invested $1.1M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
Does Infusystem Hld buy back shares?
Yes, Infusystem Hld (INFU) spent $1.2M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Infusystem Hld have outstanding?
Infusystem Hld (INFU) had 21M shares outstanding as of fiscal year 2024.
What is Infusystem Hld's current ratio?
Infusystem Hld (INFU) had a current ratio of 1.82 as of fiscal year 2024, which is generally considered healthy.
What is Infusystem Hld's debt-to-equity ratio?
Infusystem Hld (INFU) had a debt-to-equity ratio of 0.41 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Infusystem Hld's return on assets (ROA)?
Infusystem Hld (INFU) had a return on assets of 2.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Infusystem Hld's Altman Z-Score?
Infusystem Hld (INFU) has an Altman Z-Score of 2.91, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Infusystem Hld's Piotroski F-Score?
Infusystem Hld (INFU) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Infusystem Hld's earnings high quality?
Infusystem Hld (INFU) has an earnings quality ratio of 8.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Infusystem Hld cover its interest payments?
Infusystem Hld (INFU) has an interest coverage ratio of 3.9x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Infusystem Hld?
Infusystem Hld (INFU) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.